🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Join us for the ISREC-SCCL Symposium in Lausanne next week, cutting edge research will be presented covering the following topics: hallmarks of cancer, with a focus on tumor immunology and mechanism-guided therapies. @FondationIsrec EPFL Université de Lausanne Université de Genève isrec-symposium2023.epfl.ch

Such a great way of wrapping up a great and intense scientific day at #ISRECC2023!!! EPFL

Thrilled to share our preprint describing PTPRZ1 targeting CARTs for adult GBM. Congratulations to Dr Darel Martinez Bedoya who spearheaded this work, that we will hopefully soon translate in the clinic among other target specific CART products. Université de Genève HUG @FondationIsrec

Amazing Ludwig Distinguished Lecture given today by Prof. Hideho Okada spanning from basic neuroscience all the way to glioma antigen discovery and immune cell engineering. It was an honor to host him in Lausanne! Ludwig Cancer Okada Lab @ UCSF Parker Institute for Cancer Immunotherapy Université de Genève

Our newest #GBM CART paper now available Nature Cancer. No efficacy signal, but learned a lot about TME thanks to great work of @C_Alanio and others Institut Curie, Parker Institute for Cancer Immunotherapy, Penn Medicine, Penn Medicine - Abramson Cancer Center, Denis Migliorini, E. John Wherry, Beatty Lab nature.com/articles/s4301…

Very proud of our Penn Medicine - Abramson Cancer Center team and collaborators with this study! We are learning more with each patient to apply in our current dual targeting #CART trial and future trials. Here it is clear we can begin to remodel the #glioblastoma TME with #CART treatment #GBM Penn Neurosurgery

Prof Frank Winkler gave an outstanding Ludwig Lecture on Cancer Neuroscience, Pacemaker-like cells are fascinating! It was an honor to co-host him with Doug Hanahan.@uniheidelberg @dkfzheidelberg @FondationIsrec

Attend the #SITC IO Drug Development Summit! This program will explore modern #IO #drug development, study design, regulatory pathways & emerging #technologies. Session VI: Chimeric #Antigen Receptors with Moderator: Pedro Romero, MD - Novigenix. Register: lnkd.in/gexYHh5e

Join us at SITC Immuno-oncology Drug Development Summit in Boston! will be honored to be presenting at the CARs session about neurological safety Society for Immunotherapy of Cancer HUG UNIGE_en

Very excited to share our new paper Cancer Immunology Research. Congratulations to Darel Martinez Bedoya who led this study validating a novel CART approach to target #glioblastoma👏👏 Proud of my team and Darel with whom I am working since our time Penn Medicine Big thanks to @FondationIsrec for its support

Scientists from UNIGE and HUG have developed immune cells capable of targeting brain tumours. #UNIGE #cancer #research #oncology ow.ly/RbZW50TulSk

Interested in CAR T cell metabolism? Here’s our latest work with a novel MPC inhibitor Mito66. This is a great collaboration with Pedro Romero Jean-Claude Martinou and the T cell metabolism guru @MathiasWenes Université de Genève MPC Therapeutics

Honored that the Migliorini Lab. was selected to present and participate at the The Mark Foundation for Cancer Research and @sonntagfdn initiative on glioblastoma in Chicago. Proud of Valérie Dutoit who presented updates on our research program on this occasion!

Want to hear about #CARTCell therapy for the treatment of solid tumors, specifically #glioblastoma? We just spoke with Denis Migliorini and will be sharing his interview soon on our sister journal 👉VJOncology.com! #ImmunoOnc #CARTCell #CART25 The EBMT European Hematology Association

🚨Check this out🚨Amazing collaboration with Nicola Vannini, Helen Hope Carrasco, Jana de Sostoa and many others addressing aging and CAR T cell efficacy out today in Nature Cancer